Friday, November 27, 2020
Home Life Style Health & Fitness WHO Plans To Enhance It’s Combat Against Snakebites

WHO Plans To Enhance It’s Combat Against Snakebites

WHO estimates venomous snakes bite 1.8 million to 2.7 million people a year

Governments around the world plan to strike back harder against snakebite, a scourge that kills tens of thousands of people a year.

A World Health Organization (WHO) resolution raises the priority of improving snakebite prevention as well as access to effective and affordable anti-venom. The measure was approved by 192 countries in late May.

The WHO estimates that venomous snakes bite 1.8 million to 2.7 million people a year, killing between 81,000 and 138,000 of them.

“For every person who dies following a snakebite, another four or five are left with disabilities such as blindness, restricted mobility or amputation, and post-traumatic stress disorder,” the WHO reports.

Snakebite envenoming is most prevalent in sub-Saharan Africa, South Asia and Southeast Asia, the WHO reports. People in rural, impoverished areas there and elsewhere are most at risk, challenged by poor or remote health systems, and limited diagnoses, ambulances and other emergency care – including reliable anti-venom.

Grass snake
Grass snake, Flickr

In sub-Saharan Africa, just 2 percent of people bitten by venomous snakes have access to appropriate anti-venom, says Medecins Sans Frontieres (MSF), the aid group also known as Doctors Without Borders.

“We need to know better the data [on] where most cases take place,” said Julien Potet, MSF’s policy adviser on neglected tropical diseases, speaking by phone last week from Geneva. “We need to better regulate the quality of the anti-venoms, to distribute them accordingly in the areas of highest need” and to make them affordable, “because otherwise they [patients] will not be able to access the product.”

Potet pointed out that French pharmaceutical company Sanofi Pasteur has stopped manufacturing Fav-Afrique, the only serum known to effectively treat bites from some sub-Saharan African snakes. The last batches of the company’s serum expired in June 2016.

Production of the anti-venom takes roughly two years, the in-Pharma Technologist website reported. It said the pharmaceutical company cited manufacturing costs, and competition from cheaper but less effective treatments, in its decision to stop producing Fav-Afrique.

MSF has estimated that the anti-venom costs a patient $250 to $500 for treatment.

Sanofi Pasteur announced in January that it had agreed to divest its anti-venom immunoglobulin range, which includes Fav-Afrique, to the U.K.-based firm MicroPharm.

“We hope this resolution will trigger some actions to better regulate the market … and to prioritize and subsidize” anti-venom production and distribution, Potet said.

“Now we need to make sure this resolution is translated into a concrete, fully funded action plan,” he added.

A researcher demonstrates how to extract venom from a snake to vacationing school children during a presentation at the Butantan Institute in Sao Paulo, Brazil, Jan. 23, 2015
A researcher demonstrates how to extract venom from a snake to vacationing school children during a presentation at the Butantan Institute in Sao Paulo, Brazil, Jan. 23, 2015, VOA

A WHO working group is expected to offer recommendations on how governments can bolster data collection, training for health workers, access to care and support for effective anti-venoms, according to Devex, a website aimed at the global development community. It said the group’s report is expected by Nov. 30.

Also read: Australian snakes have Asian origins study

Devex also reported that David Williams, the group’s chair, estimated “about $6 million was needed in 2018-2019 to prepare the recommendations, improve surveillance, deliver antivenoms, and address other technical and medical challenges.” (VOA)

STAY CONNECTED

19,120FansLike
362FollowersFollow
1,780FollowersFollow

Most Popular

Digital Transformation Seen in Indian Firms

As pandemic accelerates digital transformation across the spectrum, a Dell Technologies report on Thursday said that 94.7 percent of Indian organizations have fast-tracked some...

Threat To Wildlife of Ganges By Waste Fishing Gear

Researchers have found that waste fishing gear in the Ganges poses a serious threat to wildlife including otters, turtles, and dolphins. The study, published in...

53% Indians Will To Switch Jobs For Remote Work

More than half of the office-goers in India are willing to switch jobs if it meant they could work remotely, said a new survey...

Doctors Suggest Flu Shots For Children & Vaccination For Adults

This year has been a double whammy. These earlier diseases are still prevalent and we have COVID added to the disease spectrum and has...

Early Birth Associated With Risks of Hospital Visit Throughout Childhood

Researchers have found that being born early is associated with a higher risk of hospital admission throughout childhood than being born at full term. Existing...

SpaceX Launches 60 More Starlink Satellites

Elon Musk-run SpaceX on Wednesday launched another successful mission carrying 60 more Starlink satellites on board a Falcon 9 rocket into low-Earth orbit that...

Space Travel Makes Cell’s Energy Production Dysfunctional

Critical parts of a cell's energy production machinery, the mitochondria, can be made dysfunctional due to space travel, says a study. The results, published in...

IT Ministry And IBM Tie Up For Education and Skilling of Youth

IBM India on Thursday said it has collaborated with the Union Ministry of Electronics and Information Technology (MeitY) to create a robust education and...

Recent Comments